Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Operations: 2020-2024

Historic Cash from Operations for Immuneering (IMRX) over the last 4 years, with Dec 2024 value amounting to -$14.5 million.

  • Immuneering's Cash from Operations fell 23.23% to -$14.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$55.0 million, marking a year-over-year decrease of 12.32%. This contributed to the annual value of -$55.0 million for FY2024, which is 12.32% down from last year.
  • As of Q4 2024, Immuneering's Cash from Operations stood at -$14.5 million, which was down 7.71% from -$13.5 million recorded in Q3 2024.
  • Over the past 5 years, Immuneering's Cash from Operations peaked at -$3.5 million during Q3 2020, and registered a low of -$15.5 million during Q1 2024.
  • Its 3-year average for Cash from Operations is -$12.3 million, with a median of -$11.9 million in 2023.
  • Data for Immuneering's Cash from Operations shows a maximum YoY plummeted of 159.17% (in 2021) over the last 5 years.
  • Immuneering's Cash from Operations (Quarterly) stood at -$5.5 million in 2020, then tumbled by 69.43% to -$9.2 million in 2021, then declined by 27.16% to -$11.7 million in 2022, then declined by 0.23% to -$11.8 million in 2023, then fell by 23.23% to -$14.5 million in 2024.
  • Its last three reported values are -$14.5 million in Q4 2024, -$13.5 million for Q3 2024, and -$11.5 million during Q2 2024.